Safety and effect of Tirofiban in patients with acute myocardial infarction treated with percutaneous coronary intervention

Objective To evaluate the safety and efficacy of Tirofiban in patients with acute myocardial infarction treated with percutaneous coronary intervention.Methods 106 acute myocardial infarction patients treated with percutaneous coronary intervention (PCI) were randomly divided into Tirofiban group (n=52) and control group(n=54).All patients took aspirin,clopidogrel and injected heparin subcutaneously.In the Tirofiban group,the drug was used within 1 hour after PCI for 36 hours.ECG,left ventricular ejection fraction (LVEF),major adverse cardiac events(MACE) and hemorrhagic incidents were observed.Results The myocardial ischemia improved in two groups,and for the Tirofiban group,there were more patients got the optimal sum STR 70 % (P0.05).Comparing with the control group,the Tirofiban group had higher LVEF and lower MACE incidence (P0.05).There was no significant difference of bleeding incidence between the two groups (P0.05).Conclusion Using Tirofiban after PCI in AMI patients,being safety and efficacy,can decrease the incidences of cardiac death,re-infarction and target vessel revascularization and improve the heart function,at the same time,dose not increase the risk of bleeding.